Shui LP, Zhu Y, Duan XQ, Chen YT, et al. HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy. J Med Virol 2023 Feb 3. doi: 10.1002/jmv.28549.
PMID: 36734081